Drug Information Analysis Service

Colten HR . Cystic fibrosis. In: Braunwald E Isselbacher KJ Petersdorf RG Wilson JD Martin JB Fauci AS . Harrison's principles of internal medicine. 11th ed. New York: McGraw-Hill, 1987: 1085–6.

Scully BE Nakatome M Ores C Davidson S Neu HC . Ciprofloxacin therapy in cystic fibrosis. Am J Med 1987; 82 (suppl 4A):196–201.

Shapiro Rubiott C . Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients. J Antimicrob Chemother 1986; 18 (suppl D):147–52.

Goldfarb J Stern RC Reed MD Yamashita TS Myers CM Blumer JL . Ciprofloxacin monotherapy for acute pulmonary exacerbation of cystic fibrosis. Am J Med 1987; 82 (suppl 4A):174–9.

Rubio TT . Ciprofloxacin: Comparative data in cystic fibrosis. Am J Med 1987; 82 (suppl 4A):185–8.

Domagala JM Hanna LD Heifetz CL . New structureactivity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. J Med Chem 1986; 29: 394–404.

Crump B Wise R Dent J . Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983; 24: 784–6.

Bender SW Dalhoff A Shah PM Strehl R Posselt HG . Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 1986; 14: 17–20.

Davis RL Koup JR Williams-Warren J . Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 915–9.

Klinger JD Aronoff SC . In vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. J Antimicrob Chemother 1985; 15: 679–84.

Smith MJ Hodson ME Batten JC . Ciprofloxacin in cystic fibrosis (letter). Lancet 1986; 2: 1103.

Bosso JA Black PG . Efficacy of ciprofloxacin in patients with cystic fibrosis. Drug Intell Clin Pharm 1988; 22: 551–3.

Hodson ME Robert CM Butland RJ Smith MJ Batten JC . Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987; 1: 235–7.

Bosso JA Black PG Matsen J . Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987; 28 (suppl):180–4.

Shalit I Stutman HR Marks MI Chartrand SA Hilman BC . Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am J Med 1987; 82 (suppl 4A):189–95.

Schluter G . Ciprofloxacin: Review of potential toxicologic effects. Am J Med 1987; 82 (suppl 4A):91–3.

Arcieri G Griffith E Gruenwaldt G . Ciprofloxacin: An update on clinical experience. Am J Med 1987; 82 (suppl 4A):381–6.

Rubinstein E Segev S . Drug interactions of ciprofloxacin with other non-antibiotic agents: Am J Med 1987; 82 (suppl 4A):119–23.

Raoof S Wollschlager C Khan FA . Treatment of respiratory tract infections with ciprofloxacin. J Antimicrob Chemother 1986; 18 (suppl D):139–45.

Raoof S Wollschlager C Khan FA . Treatment of respiratory tract infections with ciprofloxacin. J Antimicrob Chemother 1986; 18 (suppl D):139–45.

Schwartz J Jauregui L Lettieri J Bachmann K . Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. Antimicrob Agents Chemother 1988; 32: 75–7.

Wijnands WJA Vree TB Van Herwaarden CLA . The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22: 677–83.

Thomson AH Thomson GD Hepburn M Whiting B . A clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol 1987; 33: 435–6.

Rybak MJ Bowles SK Chandrasekar PH Edwards DJ . Increased theophylline concentrations secondary to ciprofloxacin. Drug Intell Clin Pharm 1987; 21: 879–81.

Vaccines and toxoids. In: AMA drug evaluations. 6th ed. Philadelphia: WB Saunders, 1986: 1106–46.

Dienstag JL Wands JR Koff RS . Acute hepatitis. In: Braunwald E Isselbacher KJ Petersdorf RG Wilson JD Martin JB Fauci AS . Harrison's principles of internal medicine. 11th ed. New York: McGraw-Hill, 1987: 325–35.

Immunization Practices Advisory Committee. Update on hepatitis B prevention. MMWR 1987; 36: 1325–35.

Szmuness W Stevens CE Harley EJ . Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980; 303: 833–41.

Francis DP Hadler SC Thompson SE . The prevention of hepatitis B with vaccine: Report for the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97: 362–6.

Hadler SC Francis DP Maynard JE . Long term immunogenicity and efficacy of hepatitis vaccine in homosexual men. N Engl J Med 1986; 315: 209–14.

Jilig W Schmidt M Deinhardt F . Hepatitis B vaccination: How long does protection last? (letter). Lancet 1984; 2: 458.

Krugman S Davidson M . Hepatitis B vaccine: Prospects for the duration of immunity. Yale J Biol Med 1987; 60: 333–8.

Laplanche A Courouce AM Benhamou E . Timing of hepatitis B revaccination in healthy adults (letter). Lancet 1987; 1: 1206–7.

Ambrosch F Frisch-Niggemeyer W Kremsner P . Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J 1987; 63 (suppl 2):129–35.

Stevens CE Alter HJ Taylor PE . Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 1984; 311: 496–501.

Matsaniotis N Kattamis C Laskari S . When should at-risk patients with thalassaemia be boosted with hepatitis B vaccine? (letter). Lancet 1987; 1: 1321.

Coursaget P Chotard J Vincelot P . Seven-year-study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986; 2: 1143–4.

Viladomiu L Genesca J Esteban JI . When should at-risk infants be boosted with hepatitis B vaccine? (letter). Lancet 1987; 1: 49.

Hollinger FB . Hepatitis B vaccines—to switch or not to switch (editorial). JAMA 1987; 257: 2634–6.

Fischer M Lorenz W Reiman HJ . Cimetidine prophylaxis of acute gastrointestinal lesions in patients at risk. In: Creutzfeldt W , ed. Cimetidine: proceedings of an international symposium on histamine H₂-receptor antagonists. Gottingen, West Germany, 1977: 280–90.

Kingsley AN . Prophylaxis for acute stress ulcers: Antacids or cimetidine. Am Surg 1985; 51: 545–7.

MacDougall BRD Bailey RJ Williams R . Histamine H₂-receptor antagonists in the prophylaxis and control of acute grastrointestinal haemorrhage in liver disease. In: Burland WL Simkins Alison M , eds. Cimetidine: proceedings of the second international symposium on histamine H₂-receptor antagonists. London, 1976: 329–36.

Ostro MJ Russell JA Soldin SJ Mahon WA Jeejeebhoy KN . Control of gastric pH with cimetidine: Bolus versus primed infusions. Gastroenterology 1985; 89: 532–7.

Peura DA Johnson LF . Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985; 103: 173–7.

Morgan DJ Uccellini DA Raymond K Mihaly GW Jones DB Smallwood RA . The influence of duration of intravenous infusion of an acute dose on plasma concentrations of cimetidine. Eur J Clin Pharmacol 1983; 25: 26–34.

Powell JR Doon KH . Histamine H₂-antagonist drug interactions in perspective: Mechanistic concepts and clinical implications. Am J Med 1984; 77 (suppl):57–84.

Penston J Wormsley KG . Adverse reactions and interactions with H₂-receptor antagonists. Med Toxicol 1986; 1: 192–216.